Specialty Pharmacy

A study including 10 million patients covered by 11 health plans suggested that insurance claims could be used to estimate the number of early-stage breast cancer cases as well as the demand for anti-HER2 drugs.

Armada Health Care (Armada), the nation's largest specialty pharmacy group purchasing and channel management organization, is pleased to announce that it is supporting the Academy of Managed Care Pharmacy (AMCP) and its efforts on biosimilars within the specialty pharmacy channel.

Specialty Pharmacy Times contributor Quintin Jessee discusses why he chose a career in specialty pharmacy and the new opportunities that are emerging in this industry.

Almost half of members spending more than $50,000 per year on drug costs were being treated with chemotherapy.

Investigators have found that patients with early tumor shrinkage and colon cancer expressing wild-type KRAS genes benefit from addition of cetuximab to standard therapy.

MedImpact Healthcare Systems, Inc and Onco360 announced a joint collaboration focused on offering MedImpact clients a unique and effective solution for bending the cost curve and delivering quality and value-based oncology pharmaceutical care.

Mark Zitter, CEO at Zitter Health Insights, explains how the growth of Accountable Care Organizations may impact specialty drug management in the near future.

The Center for Pharmacy Practice Accreditation (CPPA) recently announced the development of an accreditation program for specialty pharmacy practices.

Secukinumab is the first therapy that selectively targets IL-17A in psoriasis to complete a Phase III trial.

Employers and health plans can begin to take control of these specialty drug costs by following 7 steps outlined in a new report released today by Prime.

Negative findings were reported for both clinical and imaging measures in a Phase II randomized trial of riluzole in comparison to placebo in patients with very early multiple sclerosis (MS).

Amid legislative shutdown, some drug review operations tied to residual user fees continue, but all nonemergency activities related to biosimilars have been suspended indefinitely.

A recent study compared the annual cost per treated patient for a health plan for patients taking etanercept, adalimumab, or infliximab.

Bill Sullivan of the Specialty Pharmacy Association of America describes the growth of the specialty pharmacy industry and the factors that prompted the formation of SPAARx.

Prime Therapeutics Specialty Pharmacy LLC helped 4 in 10 members save on their drug costs by informing them of copay coupon and patient assistance programs (PAP) and applying them to their prescriptions, according to new research presented by pharmacy benefit manager Prime Therapeutics LLC (Prime).

Today, more than 30 pharmacy organizations across the globe will go on Twitter for American Pharmacists Month.

Rheumatologists in Austria and The Netherlands have proposed a reclassification of synthetic disease-modifying antirheumatic drugs (DMARDs) into targeted synthetic DMARDs and conventional synthetic DMARDs.

The 2014 10th Annual Specialty Pharmacy Summit & Expo, Hosted by Armada Health Care, is pleased to announce that individual attendee registration is now open for the conference.

Avella Specialty Pharmacy has been chosen by Navitus Health Solutions LLC to provide Synagis to its managed Medicaid members in Texas and Colorado.

Pertuzumab (Perjeta) in combination with trastuzumab and chemotherapy has become the first FDA-approved neoadjuvant treatment for patients with breast cancer.

Investigators in the Czech Republic have found an association between soft tissue lesions and diminished survival in patients with multiple myeloma.

Managed Health Care Associates, Inc (MHA) is pleased to announce that the latest release of RxPertise Consulting Software.

The Generic Pharmaceutical Association petition recommends that the FDA use the active ingredient in a reference biologic when naming a biosimilar product.

The FDA has added a new black box warning to 2 drugs, rituximab (Rituxan) and ofatumumab (Arzerra) for the potential of either drug to cause reactivation of hepatitis B virus (HBV).

Leaders from the Senate and House committees overseeing health policy announced that they have reached an agreement on legislation to help ensure the safety of compounded drugs and our nation's pharmaceutical supply chain.

Manufacturers often select their specialty drug distribution strategy based on the level of REMS reporting required by the FDA. What are some things keeping specialty pharmacies and manufacturers from collecting the data they truly want?

Michael Einodshofer of Walgreens identifies the various charges that can be included in the total cost of an infusion in a hospital setting.